Lilly Korea, Handok to copromote Cialis

Lilly Korea and Handok Pharm announced on July 12 that they entered into a letter of intent to comarket Cialis (tadalafil) in the domestic impotence market, following their strategic alliances over Cymbalta.

Cialis, an oral treatment for erectile dysfunction, is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).

This collaboration is r...